242801-86-1

Basic information

• Product Name: 4-PHENYLPIPERAZINE-1-CARBOTHIOAMIDE
• Synonyms: 4-PHENYLPIPERAZINE-1-CARBOTHIOAMIDE;AKOS BB-4445;4-phenyltetrahydro-1(2H)-pyrazinecarbothioamide
• CAS NO: 242801-86-1
• Molecular Formula: C11H15N3S
• Molecular Weight: 221.32
• Mol File: 242801-86-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-PHENYLPIPERAZINE-1-CARBOTHIOAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PHENYLPIPERAZINE-1-CARBOTHIOAMIDE(242801-86-1)
• EPA Substance Registry System: 4-PHENYLPIPERAZINE-1-CARBOTHIOAMIDE(242801-86-1)

Safety Data

• Hazardous Substances Data: 242801-86-1(Hazardous Substances Data)

Upstream product

• 92-54-6 4-phenyl-1-piperazine 

Relevant articles and documents

Design and synthesis of new donepezil analogs derived from arylpiperazine scaffold as acetylcholinesterase inhibitors

Newly synthesized 4-substituted phenyl-2-(4-substituted phenylpiperazine-1-yl)thiazole derivatives (4a–v) were evaluated in terms of their acetylcholinesterase (AChE) inhibition activities. Twenty-two compounds were tested against AChE at six different concentrations that varied between 10?4 and 10?9 M. The concentrations that inhibited AChE were calculated between 1.15 and 3.45 μM in seven compounds (4a, 4b, 4h, 4l, 4m, 4q, 4r). Compounds 4m, 4b, and 4l represented 1.15, 1.31, 1.34 μM (IC50) inhibitions, respectively. Although the inhibition values are lower than that of donepezil, they are considerable. Modeling studies of these analogs revealed similar positioning with donepezil, in which Ar–Ar interactions with Tyr337 and Trp 286 exist.

MEDICINAL COMPOSITIONS

The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

Substituted 1,3-thiazole compounds, their production and use

(1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.

CONCOMITANT DRUGS

The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammator

p38MAP KINASE INHIBITORS

A 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s) has a superior p38 MAP kinase inhibitory activity and TNF-α production inhibitory activity.